Contact us if you’d like to know more
We are more than happy to support you in case you have questions. Feel free to reach out via e-mail.
Are you a healthcare professional?
This site is intended only for Healthcare Professionals who are interested in the management of gastric cancer and/or gastro-oesophageal junction cancers.
I AM NOT A HEALTHCARE PROFESSIONAL BUT WOULD LIKE MORE INFORMATION ON GASTRIC/GASTRO-OESOPHAGEAL JUNCTION CANCERS
Both membranous stain intensity and percentage of tumour cells stained are critical for CLDN18.2 reporting1
In addition to membranous stain intensity and percentage of tumour cells stained, it is recommended that the biomarker report also include:
- The type of testing method used
- A description of the status of the sample, such as “positive,” “negative,” or “inconclusive”
- Any relevant notes or observations regarding the sample or results
Consistent, integrated reporting of biomarkers can inform clinical decision making and patient care2
Integrated biomarker reporting:
- Gives the HCP the ability to review biomarker test results that inform clinical approach
- Can be used as a tool to help pathologists educate the multidisciplinary team
References: 1. Pellino A, Brignola S, Riello E, et al. Association of CLDN18 protein expression with clinicopathological features and prognosis in advanced gastric and gastroesophageal junction adenocarcinomas. J Pers Med (Epub) 10-26-2021. 2. Warner JL, Jain SK, Levy MA. Integrating cancer genomic data into electronic health records. Genome Medicine 2016;8(113).